checkAd

     221  0 Kommentare Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients - Seite 3

    To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

    In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

    # # #

    Contact:
    LHA Investor Relations
    Kim Sutton Golodetz
    212-838-3777
    kgolodetz@lhai.com


    Seite 3 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients - Seite 3 BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) - Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation …